Lumos Pharma Announces Departure of Chief Medical Officer

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced ...

Related Keywords

Texas ,United States ,Erick Hawkins ,Duke Pitukcheewanont ,Davidb Karpf ,Lisa Miller ,Lumos Pharma ,Pisit Duke Pitukcheewanont ,Stanford University ,Nasdaq ,Global Clinical Development ,Lumos Pharma Inc ,Human Growth Foundation ,Pediatric Growth Hormone Deficiency ,Chief Medical Officer ,Senior Vice President ,Medical Affairs ,Chief Executive Officer ,Growth Hormone ,Orphan Drug Designation ,Media Contact ,Markets ,